BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tebbens JD, Azar M, Friedmann E, Lanzendörfer M, Pávek P. Mathematical Models in the Description of Pregnane X Receptor (PXR)-Regulated Cytochrome P450 Enzyme Induction. Int J Mol Sci 2018;19:E1785. [PMID: 29914136 DOI: 10.3390/ijms19061785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Fanni D, Pinna F, Gerosa C, Paribello P, Carpiniello B, Faa G, Manchia M. Anatomical distribution and expression of CYP in humans: Neuropharmacological implications. Drug Dev Res 2021;82:628-67. [PMID: 33533102 DOI: 10.1002/ddr.21778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Waring RH. Cytochrome P450: genotype to phenotype. Xenobiotica 2020;50:9-18. [PMID: 31411087 DOI: 10.1080/00498254.2019.1648911] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
3 Hatipoğlu VF. . DCDS-S 2021;14:2261. [DOI: 10.3934/dcdss.2020176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang L, Sun R, Zhang Q, Luo Q, Zeng S, Li X, Gong X, Li Y, Lu L, Hu M, Liu Z. An update on polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol 2019;15:151-65. [PMID: 30583703 DOI: 10.1080/17425255.2019.1559815] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhang L, Yan J, Liu J, Meng C, Liu F, Xia C. Panaxytriol upregulates CYP3A4 expression based on the interaction of PXR, CAR, HSP90α, and RXRα. Phytomedicine 2022;101:154097. [DOI: 10.1016/j.phymed.2022.154097] [Reference Citation Analysis]
6 Tsutsui H, Kato M, Kuramoto S, Sekiguchi N, Shindoh H, Ozeki K. Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice. Xenobiotica 2020;50:875-84. [PMID: 31885304 DOI: 10.1080/00498254.2019.1710620] [Reference Citation Analysis]
7 Zhai Q, van der Lee M, van Gelder T, Swen JJ. Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity. Front Pharmacol 2022;13:912618. [DOI: 10.3389/fphar.2022.912618] [Reference Citation Analysis]
8 Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MED. Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches. J Med Chem 2021;64:6413-522. [PMID: 34003642 DOI: 10.1021/acs.jmedchem.0c02245] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Sychterz C, Galetin A, Taskar KS. When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations. Biopharm Drug Dispos 2021;42:160-77. [PMID: 33759451 DOI: 10.1002/bdd.2272] [Reference Citation Analysis]